JGC
ANIP icon

J. Goldman & Co’s ANI Pharmaceuticals ANIP Stock Holding History

J. Goldman & Co’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-51,119
Closed -$2.82M – 407
2023
Q4 		$2.82M Buy
+51,119
New +$2.81M 0.11% 165

Other funds holding ANIP

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return
RIM
Ranger Investment Management Dallas, Texas $1.58B AUM 51% 1-Year Est. Return
GACM
Global Alpha Capital Management Montreal, Quebec, Canada $1.67B AUM 35.09% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

J. Goldman & Co's ANIP Position: Q1 2024 in Review

J. Goldman & Co sold out of ANI Pharmaceuticals (ANIP) in Q1 2024, closing a stake of 51,119 shares — an estimated $2.82M sold.

J. Goldman & Co first reported a position in ANIP in Q4 2023 and held it in 1 quarter. The position peaked at $2.82M in Q4 2023. 199 funds tracked by Wall St. Rank hold ANIP as of Q1 2024.

  • J. Goldman & Co reported no remaining ANI Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • J. Goldman & Co sold 51,119 ANI Pharmaceuticals shares in Q1 2024, an estimated $2.82M.
  • J. Goldman & Co first reported a position in ANI Pharmaceuticals in Q4 2023 and held it in 1 quarter.
  • J. Goldman & Co's ANI Pharmaceuticals position peaked at $2.82M in Q4 2023.
  • 199 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q1 2024.

Based on J. Goldman & Co's 13F filing for Q1 2024, filed 15 May 2024.